Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jay M Lee

Showing results (81-90 of 93) with videos related to

Pageof 10
Sort By:
Journal of Cardiovascular Electrophysiology|June 20, 2020
Recurrent ventricular tachycardia after cardiac sympathetic denervation: Prolonged cycle length with improved hemodynamic tolerance and ablation outcomesJustin Hayase, Veronica Dusi, Duc Do, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 6, 2009
Snail promotes CXCR2 ligand-dependent tumor progression in non-small cell lung carcinomaJane Yanagawa, Tonya C Walser, Li X Zhu, et al.
American Journal of Translational Research|August 27, 2013
Elevated neutrophil gelatinase-associated lipocalin contributes to erlotinib resistance in non-small cell lung cancerKostyantyn Krysan, Xiaoyan Cui, Brian K Gardner, et al.
Cancer Research|May 31, 2019
The Immune Contexture Associates with the Genomic Landscape in Lung Adenomatous PremalignancyKostyantyn Krysan, Linh M Tran, Brandon S Grimes, et al.
Cancer Research Communications|March 21, 2025
The Impact of the Tumor Microenvironment on the Effect of IL-1β Blockade in NSCLC: Biomarker Analyses from CANOPY-1 and CANOPY-N TrialsBenjamin J Solomon, Daniel S W Tan, Gilberto de Castro, et al.
International Journal of Radiation Oncology, Biology, Physics|April 6, 2023
Safety and Efficacy Results From iSABR, a Phase 1 Study of Stereotactic ABlative Radiotherapy in Combination With Durvalumab for Early-Stage Medically Inoperable Non-Small Cell Lung CancerTrudy C Wu, Annalise Stube, Carol Felix, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 5, 2017
Phase I Trial of Intratumoral Injection of <i>CCL21</i> Gene-Modified Dendritic Cells in Lung Cancer Elicits Tumor-Specific Immune Responses and CD8<sup>+</sup> T-cell InfiltrationJay M Lee, Mi-Heon Lee, Edward Garon, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|December 9, 2023
Artificial Intelligence-Powered Assessment of Pathologic Response to Neoadjuvant Atezolizumab in Patients With NSCLC: Results From the LCMC3 StudySanja Dacic, William D Travis, Jennifer M Giltnane, et al.
Nature Medicine|October 10, 2023
Author Correction: Neoadjuvant atezolizumab for resectable non-small cell lung cancer: an open-label, single-arm phase II trialJamie E Chaft, Filiz Oezkan, Mark G Kris, et al.
Nature Medicine|September 13, 2022
Neoadjuvant atezolizumab for resectable non-small cell lung cancer: an open-label, single-arm phase II trialJamie E Chaft, Filiz Oezkan, Mark G Kris, et al.
Pageof 10

Showing results (81-90 of 93) with videos related to

Sort By:
Pageof 10
Journal of Cardiovascular Electrophysiology|June 20, 2020
Recurrent ventricular tachycardia after cardiac sympathetic denervation: Prolonged cycle length with improved hemodynamic tolerance and ablation outcomesJustin Hayase, Veronica Dusi, Duc Do, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 6, 2009
Snail promotes CXCR2 ligand-dependent tumor progression in non-small cell lung carcinomaJane Yanagawa, Tonya C Walser, Li X Zhu, et al.
American Journal of Translational Research|August 27, 2013
Elevated neutrophil gelatinase-associated lipocalin contributes to erlotinib resistance in non-small cell lung cancerKostyantyn Krysan, Xiaoyan Cui, Brian K Gardner, et al.
Cancer Research|May 31, 2019
The Immune Contexture Associates with the Genomic Landscape in Lung Adenomatous PremalignancyKostyantyn Krysan, Linh M Tran, Brandon S Grimes, et al.
Cancer Research Communications|March 21, 2025
The Impact of the Tumor Microenvironment on the Effect of IL-1β Blockade in NSCLC: Biomarker Analyses from CANOPY-1 and CANOPY-N TrialsBenjamin J Solomon, Daniel S W Tan, Gilberto de Castro, et al.
International Journal of Radiation Oncology, Biology, Physics|April 6, 2023
Safety and Efficacy Results From iSABR, a Phase 1 Study of Stereotactic ABlative Radiotherapy in Combination With Durvalumab for Early-Stage Medically Inoperable Non-Small Cell Lung CancerTrudy C Wu, Annalise Stube, Carol Felix, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 5, 2017
Phase I Trial of Intratumoral Injection of <i>CCL21</i> Gene-Modified Dendritic Cells in Lung Cancer Elicits Tumor-Specific Immune Responses and CD8<sup>+</sup> T-cell InfiltrationJay M Lee, Mi-Heon Lee, Edward Garon, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|December 9, 2023
Artificial Intelligence-Powered Assessment of Pathologic Response to Neoadjuvant Atezolizumab in Patients With NSCLC: Results From the LCMC3 StudySanja Dacic, William D Travis, Jennifer M Giltnane, et al.
Nature Medicine|October 10, 2023
Author Correction: Neoadjuvant atezolizumab for resectable non-small cell lung cancer: an open-label, single-arm phase II trialJamie E Chaft, Filiz Oezkan, Mark G Kris, et al.
Nature Medicine|September 13, 2022
Neoadjuvant atezolizumab for resectable non-small cell lung cancer: an open-label, single-arm phase II trialJamie E Chaft, Filiz Oezkan, Mark G Kris, et al.
Pageof 10